272 related articles for article (PubMed ID: 21347793)
1. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer.
Lin WL; Kuo WH; Chen FL; Lee MY; Ruan A; Tyan YS; Hsu JD; Chiang H; Han CP
Ann Surg Oncol; 2011 Aug; 18(8):2388-94. PubMed ID: 21347793
[TBL] [Abstract][Full Text] [Related]
2. HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer.
Chao WR; Lee MY; Lin WL; Chen CK; Lin JC; Koo CL; Sheu GT; Han CP
Hum Pathol; 2014 Apr; 45(4):810-6. PubMed ID: 24656091
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
[TBL] [Abstract][Full Text] [Related]
4. The HER2 gene copies per tumor cell either before or after correction for chromosome-17 correlated significantly with HER2 IHC results in epithelial ovarian cancer in a tissue microarray study.
Tsai WC; Lee MY; Chen FL; Wang PH; Lin WL; Ruan A; Li YJ; Wang SC; Chiang H; Han CP
Arch Gynecol Obstet; 2011 Sep; 284(3):721-9. PubMed ID: 21046136
[TBL] [Abstract][Full Text] [Related]
5. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ
Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
[TBL] [Abstract][Full Text] [Related]
7. Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization.
Lin CK; Lin WL; Chen FL; Lee MY; Kuo JF; Ruan A; Tyan YS; Chiang H; Chou MC; Han CP
Int J Gynecol Pathol; 2011 Jul; 30(4):372-9. PubMed ID: 21623202
[TBL] [Abstract][Full Text] [Related]
8. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
Karaferic A; Jovanovic D; Jelic S
J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
[TBL] [Abstract][Full Text] [Related]
9. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
11. Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer.
Nadkarni NJ; Geest KD; Neff T; Young BD; Bender DP; Ahmed A; Smith BJ; Button A; Goodheart MJ
Cancer Lett; 2013 Apr; 331(1):99-104. PubMed ID: 23268330
[TBL] [Abstract][Full Text] [Related]
12. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
[TBL] [Abstract][Full Text] [Related]
13. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas.
Clauditz TS; Reiff M; Gravert L; Gnoss A; Tsourlakis MC; Münscher A; Sauter G; Bokemeyer C; Knecht R; Wilczak W
Pathology; 2011 Aug; 43(5):459-64. PubMed ID: 21670724
[TBL] [Abstract][Full Text] [Related]
14. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.
Enomoto T; Weghorst CM; Inoue M; Tanizawa O; Rice JM
Am J Pathol; 1991 Oct; 139(4):777-85. PubMed ID: 1656759
[TBL] [Abstract][Full Text] [Related]
15. The AA genotype of a L1C G842A polymorphism is associated with an increased risk for ovarian cancer.
Heubner M; Wimberger P; Kasimir-Bauer S; Otterbach F; Kimmig R; Siffert W
Anticancer Res; 2009 Aug; 29(8):3449-52. PubMed ID: 19661372
[TBL] [Abstract][Full Text] [Related]
16. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours.
Yan B; Choo SN; Mulyadi P; Srivastava S; Ong CW; Yong KJ; Putti T; Salto-Tellez M; Lim GS
J Clin Pathol; 2011 Dec; 64(12):1097-101. PubMed ID: 21896578
[TBL] [Abstract][Full Text] [Related]
17. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.
Anglesio MS; Kommoss S; Tolcher MC; Clarke B; Galletta L; Porter H; Damaraju S; Fereday S; Winterhoff BJ; Kalloger SE; Senz J; Yang W; Steed H; Allo G; Ferguson S; Shaw P; Teoman A; Garcia JJ; Schoolmeester JK; Bakkum-Gamez J; Tinker AV; Bowtell DD; Huntsman DG; Gilks CB; McAlpine JN
J Pathol; 2013 Jan; 229(1):111-20. PubMed ID: 22899400
[TBL] [Abstract][Full Text] [Related]
19. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
[TBL] [Abstract][Full Text] [Related]
20. HER2/ ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors.
Smithgall MC; Yemelyanova A; Mathew S; Gogineni S; He B; Zhang T; Robinson BD; Tu JJ
Int J Gynecol Pathol; 2024 Mar; 43(2):134-139. PubMed ID: 37406458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
